Inclusion Criteria

Concurrent Medication:

Required:

• PCP prophylaxis.

Allowed:

• Topical or oral antifungal agents (other than oral ketoconazole).
• Approved agents for opportunistic infections.
• Antibiotics unless specifically excluded.
• Systemic corticosteroids for no more than 21 days.
• Vitamins.
• Recombinant erythropoietin.
• G-CSF.
• Regularly prescribed medications such as allergy medications, antidepressants, antipyretics, analgesics, oral contraceptives, megestrol, and testosterone.

Concurrent Treatment:

Allowed:

• Acupuncture.
• Visualization techniques.

Patients must have:

• HIV infection.
• CD4 count <= 200 cells/mm3.
• At least 6 months total prior AZT therapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Malignancy requiring systemic therapy other than minimal Kaposi's sarcoma.

Concurrent Medication:

Excluded:

• Antiretrovirals other than study drugs.
• Rifabutin and rifampin.
• Investigational drugs other than indinavir sulfate.
• Systemic cytotoxic chemotherapy.
• Oral ketoconazole.
• Chronic systemic corticosteroids.
• Herbal therapies.

Patients with the following prior conditions are excluded:

• Unexplained temperature > 38.5 C for any 7 days within 30 days prior to study entry.
• Chronic diarrhea persisting for 15 days within 30 days prior to study entry.
• History of acute or chronic pancreatitis.
• Acute hepatitis within 30 days prior to study entry.
• Grade 2 or worse bilateral peripheral neuropathy within 60 days prior to study entry.
• Dose-limiting intolerance to prior AZT at 600 mg/day.

Prior Medication:

Excluded:

• More than 1 week of prior 3TC.
• Any prior protease inhibitors.
• Rifampin or rifabutin within 14 days prior to study entry.

Excluded within 30 days prior to study entry:

• Erythropoietin.
• G-CSF or GM-CSF.
• Non-nucleoside reverse transcriptase inhibitors.
• Interferons.
• Interleukins.
• HIV vaccines.
• Any experimental therapy.